摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

i-Propyl-2-methylallylaether | 44744-50-5

中文名称
——
中文别名
——
英文名称
i-Propyl-2-methylallylaether
英文别名
3-isopropoxy-2-methyl-propene;isopropyl-methallyl ether;Isopropyl-methallyl-aether;2-Methyl-propen-(1)-ol-(3)-isoproplyaether;3-Isopropyloxy-2-methyl-propen-(1);1-Propene, 2-methyl-3-(1-methylethoxy)-;2-methyl-3-propan-2-yloxyprop-1-ene
i-Propyl-2-methylallylaether化学式
CAS
44744-50-5
化学式
C7H14O
mdl
——
分子量
114.188
InChiKey
MJBXPPHYBBTMDB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    103.8-104.2 °C
  • 密度:
    0.7742 g/cm3

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    8
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.71
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] ARYL SULFONOHYDRAZIDES<br/>[FR] ARYL-SULFONOHYDRAZIDES
    申请人:UNIV MONASH
    公开号:WO2016198507A1
    公开(公告)日:2016-12-15
    Compound of formula (I) wherein A is selected from (i), where RF1 is H or F; (ii); (iii) a N-containing C6 heteroaryl group; and B is (B), where X1 is either CRF2 or N, where RF2 is H or F; X2 is either CR3 or N, where R3 is selected from H, Me, CI, F OMe; X3 is either CH or N; X4 is either CRF3 or N, where RF3 is H or F; where only one or two of X1, X2, X3 and X4 may be N; and R4 is selected from I, optionally substituted phenyl, optionally substituted C5-6 heteroaryl; optionally substituted C1-6 aIkyI and optionally substituted C1-6 alkoxy, which are useful in the treatment of a condition ameliorated by the inhibition of MOZ.
    化合物的结构式(I),其中A从(i)中选择,其中RF1为H或F;(ii);(iii)含氮的C6杂环芳基团;B为(B),其中X1为CRF2或N,其中RF2为H或F;X2为CR3或N,其中R3从H,Me,CI,F OMe中选择;X3为CH或N;X4为CRF3或N,其中RF3为H或F;其中X1、X2、X3和X4中仅有一个或两个可能为N;R4从I,可选择取代的苯基,可选择取代的C5-6杂环芳基;可选择取代的C1-6烷基和可选择取代的C1-6烷氧基中选择,这些化合物在通过抑制MOZ改善的疾病治疗中有用。
  • Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
    申请人:Saksena K. Anil
    公开号:US20070032433A1
    公开(公告)日:2007-02-08
    The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    本发明揭示了具有HCV蛋白酶抑制活性的新化合物,以及制备这些化合物的方法。在另一种实施方式中,本发明揭示了包含这些化合物的药物组合物,以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
  • Inhibitors of human immunodeficiency virus replication
    申请人:TSANTRIZOS Youla S.
    公开号:US20080221159A1
    公开(公告)日:2008-09-11
    Compounds of formula I: wherein a, b, c, X, R 2 , R 3 , R 4 , R 6 and R 7 are defined herein, are useful as inhibitors of HIV replication.
    式I的化合物:其中a、b、c、X、R2、R3、R4、R6和R7如此定义,对于抑制HIV复制是有用的。
  • NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS
    申请人:Saksena Anil K.
    公开号:US20110117057A1
    公开(公告)日:2011-05-19
    The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    本发明披露了具有HCV蛋白酶抑制活性的新化合物,以及制备这些化合物的方法。在另一种实施方式中,本发明披露了包含这些化合物的制药组合物,以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
  • Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
    申请人:BIOPROJET
    公开号:EP1870405A1
    公开(公告)日:2007-12-26
    The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent.
    本发明涉及通式 (I) 的化合物: 以及将其用作治疗剂的方法。
查看更多